Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

Preetesh Jain, Holly A Hill, Chi Young Ok, Alexander Nesmalov, Vitaly Segodin, Dmitry Tabakov, Nikita Kotlov, Pavel Zemskiy, Eleonora Belykh, Krystle Nomie, Ahmed Fetooh, Rashmi Kanagal-Shamanna, Fatima Z Jelloul, Guilin Tang, Francisco Vega, Nathan Fowler, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2023-181319

Published: 2023

Journal Articles

A Novel Comprehensive Tumor-Informed Plasma cfDNA Assay to Monitor Minimal Residual Disease for Hematological and Solid Malignancies

Anastasiya Yudina, Anastasiya Danchurova, Lolita Alekseeva, Aleksei Efremov, Sergei Starikov, Danielle Sookiasian, Ekaterina Nuzhdina, Svetlana Podsvirova, Madison Chasse, Tori Conroy, Noel English, Dmitry Tabakov, Sheila T. Yong, Artur Baisangurov, Cagdas Tazearslan, Nathan Fowler, Alexander Bagaev

Blood (2023) 142 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2023-174909

Published: 2023

Journal Articles

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2023-185038

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

Dai Chihara, Kumudha Balakrishnan, Gita Masand, Anna Novokreshchenova, Alexander Bagaev, Nikita Kotlov, Ekaterina Postovalova, Eduardo Shugaev-Mendosa, Yuliya Gracheva, Anna Love, Krystle Nomie, Nathan Fowler, Christopher R. Flowers, Jason Westin

Blood (2023) 142 (Supplement 1): 7155.

https://doi.org/10.1182/blood-2023-189426

Published: 2023

Journal Articles

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Rakesh Awasthi, Edward Waldron, Stephan Grupp, Michael A. Pulsipher, Peter Bader, Stephen J Schuster, Richard T Maziarz, Edmund K. Waller, Ulrich Jaeger, Catherine Thieblemont, Martin Dreyling, Nathan Fowler, Harald Jakob Maier, Jennifer Willert

Blood (2023) 142 (Supplement 1): 4872.

https://doi.org/10.1182/blood-2023-181663

Published: 2023

Journal Articles

Kinase inhibitors in CLL: drawing the roadmap

Nathan Fowler

Blood (2021) 137 (20): 2717–2719.

https://doi.org/10.1182/blood.2020010052

Published: 2021

Journal Articles

BCL-2 inhibition in follicular lymphoma: can we tip the scales?

Nathan Fowler

Blood (2020) 136 (23): 2598–2600.

https://doi.org/10.1182/blood.2020008194

Published: 2020

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2017) 130 (Supplement 1): 4037.

https://doi.org/10.1182/blood.V130.Suppl_1.4037.4037

Published: 2017

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert W Chen, MD, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, M. Lia Palomba, MD

Blood (2016) 128 (22): 1804.

https://doi.org/10.1182/blood.V128.22.1804.1804

Published: 2016

Journal Articles

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Bei Hu, MD, Anas Younes, MD, Linda Claret, Lei Feng, MS, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, Amanda R Copeland, RN, MSN, CNS, Michelle A Fanale, MD, Yasuhiro Oki, MD

Blood (2016) 128 (22): 1833.

https://doi.org/10.1182/blood.V128.22.1833.1833

Published: 2016

Journal Articles

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Ajay K. Gopal, MD, Stephen J. Schuster, MD, Nathan Fowler, MD, Judith Trotman, MBChB, Georg Hess, MD, Jing-Zhou Hou, Abdulraheem Yacoub, MD, Michael Lill, MD BS, Peter Martin, MD, Umberto Vitolo, MD, Wojciech Jurczak, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, Dzhelil Osmanov, MD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Shean-sheng Wang, PhD, Sanjay Deshpande, MD, Gilles A. Salles

Blood (2016) 128 (22): 1217.

https://doi.org/10.1182/blood.V128.22.1217.1217

Published: 2016

Journal Articles

High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience

Blood (2016) 128 (22): 106.

https://doi.org/10.1182/blood.V128.22.106.106

Published: 2016

Journal Articles

The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma

Dai Chihara, MD PhD, Michelle A Fanale, MD, Roberto N. Miranda, MD, Mansoor Noorani, Jason R. Westin, MD, Loretta J. Nastoupil, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jorge E. Romaguera, MD, Felipe Samaniego, MD, Francesco Turturro, MD, Hun Ju Lee, MD, Sattva S. Neelapu, MD, Alma Rodriguez, MD, Michael Wang, MD, Nathan Fowler, MD, L. Jeffrey Medeiros, MD, Richard Eric Davis, MD, Yasuhiro Oki, MD

Blood (2016) 128 (22): 4153.

https://doi.org/10.1182/blood.V128.22.4153.4153

Published: 2016

Journal Articles

Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib)

Preetesh Jain, MBBS,MDDM,PhD, Rashmi Kanagal-Shamanna, MD, Francis San Lucas, Michael Wang, MD, Jorge E. Romaguera, MD, Luis E. Fayad, MD, Yasuhiro Oki, MD, Jason R. Westin, MD, Jeffrey Medeiros, MD, Nathan Fowler, MD

Blood (2016) 128 (22): 2975.

https://doi.org/10.1182/blood.V128.22.2975.2975

Published: 2016

Journal Articles

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

Blood (2016) 128 (22): 4208.

https://doi.org/10.1182/blood.V128.22.4208.4208

Published: 2016

Journal Articles

The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma

Blood (2015) 126 (23): 2738.

https://doi.org/10.1182/blood.V126.23.2738.2738

Published: 2015

Journal Articles

A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma

Nathan Fowler, MD, Raisa M. Pinto, MD, Chan Yoon Cheah, MD, Sattva S. Neelapu, MD, Francesco Turturro, MD, Fredrick B. Hagemeister, MD, Jorge E. Romaguera, MD, Michelle A. Fanale, Luis E. Fayad, MD, Sheryl Forbes, Janine Khan, Lei Feng, MS, Felipe Samaniego, MD, Loretta Nastoupil, MD

Blood (2015) 126 (23): 2742.

https://doi.org/10.1182/blood.V126.23.2742.2742

Published: 2015

NARROW

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

A Novel Comprehensive Tumor-Informed Plasma cfDNA Assay to Monitor Minimal Residual Disease for Hematological and Solid Malignancies

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Kinase inhibitors in CLL: drawing the roadmap

BCL-2 inhibition in follicular lymphoma: can we tip the scales?

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience

The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma

Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib)

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma

A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only